A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
Launched by ELI LILLY AND COMPANY · Jun 12, 2019
Trial Information
Current as of July 04, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have completed (neo) adjuvant endocrine therapy and have cancer return after at least 12 months or have de novo cancer that has spread to other organs at diagnosis
- * Participants must have 1 or more of the following:
- • A high grade tumor in tissue
- • Negative progesterone receptor (PR) status
- • Have cancer that has spread to the liver
- • Have a treatment-free interval (TFI) \<36 months
- • Participants must have HR+, HER2- breast cancer
- • Participants must have adequate organ function
- Exclusion Criteria:
- • Participants must not have cancer that has spread to other organs that has severely affected their function
- • Participants must not have cancer that has spread to the brain that is unstable or untreated
- • Participants must not have received endocrine therapy in the metastatic setting
- • Participants must not have known active infection
- • Participants must not have received prior endocrine therapy and had disease return within 12 months from completion of treatment
- • Participants must not have received prior treatment with any cyclin-dependent kinase (CDK) 4 \& 6 inhibitor or everolimus
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Harvey, Illinois, United States
Palm Springs, California, United States
Fort Myers, Florida, United States
Colorado Springs, Colorado, United States
Lewiston, Maine, United States
Tyler, Texas, United States
Norfolk, Virginia, United States
Henderson, Nevada, United States
Fort Worth, Texas, United States
The Woodlands, Texas, United States
Austin, Texas, United States
Niles, Illinois, United States
York, Maine, United States
Orange, California, United States
Torrance, California, United States
Taichung, , Taiwan
Taichung, , Taiwan
Tainan, , Taiwan
Taipei, , Taiwan
Amarillo, Texas, United States
West Palm Beach, Florida, United States
Highland, California, United States
Indianapolis, Indiana, United States
Plano, Texas, United States
Fountain Valley, California, United States
Charleston, South Carolina, United States
Dallas, Texas, United States
Arlington, Texas, United States
Plano, Texas, United States
Dallas, Texas, United States
Padova, , Italy
Mcallen, Texas, United States
Bedford, Texas, United States
Abilene, Texas, United States
Houston, Texas, United States
Savannah, Georgia, United States
Pensacola, Florida, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Saint Petersburg, Florida, United States
Milano, , Italy
Dallas, Texas, United States
Monterey, California, United States
Johnson City, New York, United States
Paris, Texas, United States
Kansas City, Missouri, United States
Newark, Delaware, United States
Wien, , Austria
Ottignies, , Belgium
Caba, Ciudad Autonoma Buenos Aires, Argentina
San Juan, , Argentina
Graz, Steiermark, Austria
Clearwater, Florida, United States
Winchester, Virginia, United States
Salem, Virginia, United States
Weston, Florida, United States
Sherman, Texas, United States
Omaha, Nebraska, United States
Bayamon, , Puerto Rico
Fresno, California, United States
Ponce, , Puerto Rico
Leipzig, Sachsen, Germany
Santa Barbara, California, United States
Bologna, , Italy
Candiolo, Torino, Italy
Tallahassee, Florida, United States
Ijui, Rio Grande Do Sul, Brazil
Barretos, Sao Paulo, Brazil
Sao Jose Rio Preto, Sao Paulo, Brazil
São Paulo, , Brazil
Wichita Falls, Texas, United States
Salzburg, , Austria
Genova, , Italy
Daphne, Alabama, United States
Tempe, Arizona, United States
San Marcos, California, United States
Saint Augustine, Florida, United States
Mesquite, Texas, United States
Webster, Texas, United States
Fredericksburg, Virginia, United States
Berazategui, Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, , Argentina
Salta, , Argentina
Innsbruck, Tirol, Austria
Brugge, , Belgium
Haine St. Paul, , Belgium
Ieper, , Belgium
Londrina, Parana, Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Rio De Janeiro, Rj, Brazil
Augsburg, Bavaria, Germany
Napoli, Naples, Italy
Taichung, , Taiwan
Flower Mound, Texas, United States
Lone Tree, Colorado, United States
Midland, Texas, United States
Caba, Buenos Aires, Argentina
Kaohsiung, , Taiwan
Houston, Texas, United States
Paramus, New Jersey, United States
Horsham, Pennsylvania, United States
Dallas, Texas, United States
Dallas, Texas, United States
El Paso, Texas, United States
Mckinney, Texas, United States
San Antonio, Texas, United States
Saint George, Utah, United States
San Miguel De Tucumán, Tucuman, Argentina
Tucumain, , Argentina
Salvador, Bahia, Brazil
Lajeado, Rs, Brazil
Santo Andre, Sp, Brazil
Ribeirao Preto, São Paulo, Brazil
Rio De Janeiro, , Brazil
Sao Paulo, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Paderborn, , Germany
Udine, , Italy
Taipei, , Taiwan
Ribeirao Preto, , Brazil
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials